Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719130 | 0.95 | KDM4E (0.31) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL19425845 | 0.93 | KDM4E (0.33) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL19863963 | 0.88 | CNR2 (0.33) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL19497734 | 0.85 | — | — | |
| SCHEMBL18415105 | 0.83 | CNR2 (0.32) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL19646339 | 0.81 | MAPT (0.31) | MAPT | |
| SCHEMBL19646073 | 0.79 | KDM4E (0.38) | KDM4EMAPTHPGD | |
| SCHEMBL21719396 | 0.77 | — | — | |
| SCHEMBL21719318 | 0.77 | MAPT (0.30) | MAPT | |
| SCHEMBL25101245 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | KDM4E 1531/4885MAPT 1976/4885HPGD 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.